Suppliers / Marksans Pharma

Marksans Pharma

India MARKSANS.BO Updated 9 July 2026

Marksans Pharma is a finished-dose manufacturer based in India. It appears in 132 regulatory filings across 4 regulators, without an active US DMF or CEP on file. Its filings concentrate with DAV (Vietnam), US FDA and DIGEMAPS (DO). Its GMP standing is certified by US FDA, EMA and MHRA (UK). Its most recent recorded inspection, by US FDA, closed on 7 November 2025 as NAI. Customs aggregates show $139.0M of exports covering 4,709 molecules to 18 destinations in 2025.

0
active US DMFs
0
valid CEPs
3
registered plants 2 with an FDA FEI number
132
filings across 4 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
7 of 7 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 7 November 2025 NAI US FDA
  • 17 April 2024 VAI US FDA
  • 4 August 2023 VAI US FDA
  • 7 April 2017 VAI US FDA
  • 3 September 2015 NAI US FDA
  • 3 August 2012 NAI US FDA
  • 13 November 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Verna, India 3023677905
Verna, India 3006230648
Vasco Da Gama, India Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
DAV (Vietnam) 74 None
US FDA 25 2
DIGEMAPS (DO) 20 None
ARCSA (EC) 13 None
EMA None 1
MHRA (UK) None 1

Scale

Year Revenue Exports Destinations
2025 $301.0M $139.0M 18
2024 $260.2M $126.4M 19
2023 $224.3M $91.3M 24
2022 Not reported $85.9M 21

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Comparing suppliers?

Choose your molecules and target markets. Marksans Pharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 7 November 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts
Company filings
Revenue as reported